The activation of the pathway causes the proteasomal degradation of inhibitors (IκBα, β or ε) [115], letting the NF-κB dimer enter the nucleus and trigger genes accountable for targeting cancer cells and pro-inflammatory transcription programs [116]. The gene discussed is NFKB1; the disease is cancer.